Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

958 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
Alejo S, Palacios BE, Venkata PP, He Y, Li W, Johnson JD, Chen Y, Jayamohan S, Pratap UP, Clarke K, Zou Y, Lv Y, Weldon K, Viswanadhapalli S, Lai Z, Ye Z, Chen Y, Gilbert AR, Suzuki T, Tekmal RR, Zhao W, Zheng S, Vadlamudi RK, Brenner AJ, Sareddy GR. Alejo S, et al. Among authors: johnson jd. Neuro Oncol. 2023 Jul 6;25(7):1249-1261. doi: 10.1093/neuonc/noad018. Neuro Oncol. 2023. PMID: 36652263 Free PMC article.
Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP, Jayamohan S, He Y, Alejo S, Johnson JD, Palacios BE, Pratap UP, Chen Y, Liu Z, Zou Y, Lai Z, Suzuki T, Viswanadhapalli S, Weintraub ST, Palakurthi S, Valente PT, Tekmal RR, Kost ER, Vadlamudi RK, Sareddy GR. Venkata PP, et al. Among authors: johnson jd. Cancer Lett. 2023 Oct 28;575:216383. doi: 10.1016/j.canlet.2023.216383. Epub 2023 Sep 14. Cancer Lett. 2023. PMID: 37714256 Free PMC article.
KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer.
Chen Y, Johnson JD, Jayamohan S, He Y, Venkata PP, Jamwal D, Alejo S, Zou Y, Lai Z, Viswanadhapalli S, Vadlamudi RK, Kost E, Sareddy GR. Chen Y, et al. Among authors: johnson jd. Mol Carcinog. 2024 Oct;63(10):2026-2039. doi: 10.1002/mc.23792. Epub 2024 Jul 11. Mol Carcinog. 2024. PMID: 38990091
The discovery and characterization of HBS-101, a novel inhibitor of midkine, as a therapeutic agent for the treatment of triple negative breast cancer.
Mahajan M, Rodriguez Sanchez AL, Jayamohan S, Vijayan DK, Johnson JD, Xie H, Wang Y, Liang D, Sanchez JR, Subbarayalu P, Rao MK, Vadlamudi RK, Sareddy GR, Nair HB, Viswanadhapalli S. Mahajan M, et al. Among authors: johnson jd. Mol Cancer Ther. 2025 Apr 30. doi: 10.1158/1535-7163.MCT-25-0130. Online ahead of print. Mol Cancer Ther. 2025. PMID: 40304496
Eukaryotic translation initiation factor 2A protects pancreatic beta cells during endoplasmic reticulum stress while rescuing global translation inhibition.
Panzhinskiy E, Skovsø S, Cen HH, Rahardjo A, Zhang JA, Chu KY, MacDonald K, Soukhatcheva G, Dionne DA, Hallmaier-Wacker LK, Wildi JS, Marcil S, Noursadeghi N, Taghizadeh F, Verchere CB, Jan E, Johnson JD. Panzhinskiy E, et al. Among authors: johnson jd. Diabetologia. 2025 Apr 30. doi: 10.1007/s00125-025-06431-5. Online ahead of print. Diabetologia. 2025. PMID: 40304759
958 results